Quanterix Expands Capabilities with Strategic Acquisition of EMISSION
Quanterix (NASDAQ: QTRX) announced the acquisition of EMISSION, a Georgetown, TX-based manufacturer of magnetic beads for diagnostic assays. The acquisition, valued at $10 million upfront with potential additional payments of up to $60 million based on technical and performance milestones, is expected to close in January 2025.
This strategic move aims to vertically integrate EMISSION's proprietary bead technology, securing core components for Quanterix's next-generation Simoa platform and enabling OEM opportunities with third-party platforms. The transaction is anticipated to be accretive to revenue and gross margins in 2026.
Quanterix (NASDAQ: QTRX) ha annunciato l'acquisizione di EMISSION, un produttore di microsfere magnetiche per test diagnostici con sede a Georgetown, TX. L'acquisizione, valutata 10 milioni di dollari iniziali con potenziali pagamenti aggiuntivi fino a 60 milioni di dollari in base a traguardi tecnici e di performance, dovrebbe concludersi a gennaio 2025.
Questa mossa strategica ha l'obiettivo di integrare verticalmente la tecnologia proprietaria delle microsfere di EMISSION, assicurando componenti chiave per la piattaforma Simoa di nuova generazione di Quanterix e aprendo opportunità OEM con piattaforme di terze parti. Si prevede che la transazione sarà redditizia per i ricavi e i margini lordi nel 2026.
Quanterix (NASDAQ: QTRX) anunció la adquisición de EMISSION, un fabricante de perlas magnéticas para ensayos de diagnóstico con sede en Georgetown, TX. La adquisición, valorada en 10 millones de dólares por adelantado con pagos adicionales de hasta 60 millones de dólares basados en hitos técnicos y de rendimiento, se espera que se cierre en enero de 2025.
Este movimiento estratégico tiene como objetivo integrar verticalmente la tecnología de perlas propietarias de EMISSION, asegurando componentes clave para la plataforma Simoa de nueva generación de Quanterix y habilitando oportunidades OEM con plataformas de terceros. Se anticipa que la transacción será accretiva a los ingresos y márgenes brutos en 2026.
Quanterix (NASDAQ: QTRX)는 진단 분석을 위한 자성 비드를 제조하는 텍사스주 조지타운에 위치한 EMISSION의 인수를 발표했습니다. 이 인수는 초기 비용 1천만 달러에 기술 및 성과 이정표에 따라 최대 6천만 달러의 추가 지급 가능성이 있는 것으로 평가되며, 2025년 1월에 마무리될 것으로 예상됩니다.
이 전략적 움직임은 EMISSION의 독점 비드 기술을 수직적으로 통합하여 Quanterix의 차세대 Simoa 플랫폼을 위한 핵심 구성 요소를 확보하고 제3자 플랫폼과의 OEM 기회를 가능하게 하는 것을 목표로 하고 있습니다. 이 거래는 2026년에 수익과 총 마진에서 긍정적인 영향을 미칠 것으로 예상됩니다.
Quanterix (NASDAQ: QTRX) a annoncé l'acquisition de EMISSION, un fabricant de billes magnétiques pour des tests diagnostiques basé à Georgetown, au Texas. L'acquisition, évaluée à 10 millions de dollars au départ avec des paiements supplémentaires potentiels allant jusqu'à 60 millions de dollars en fonction de jalons techniques et de performance, devrait se clôturer en janvier 2025.
Ce mouvement stratégique vise à intégrer verticalement la technologie exclusive des billes d'EMISSION, garantissant des composants clés pour la plateforme Simoa de nouvelle génération de Quanterix et permettant des opportunités OEM avec des plateformes tierces. La transaction devrait être bénéfique pour les revenus et les marges brutes en 2026.
Quanterix (NASDAQ: QTRX) gab die Übernahme von EMISSION bekannt, einem Hersteller von magnetischen Perlen für diagnostische Tests mit Sitz in Georgetown, TX. Die Übernahme wird mit 10 Millionen Dollar im Voraus bewertet, mit potenziellen Zusatzzahlungen von bis zu 60 Millionen Dollar, die an technische und leistungsbezogene Meilensteine geknüpft sind, und soll im Januar 2025 abgeschlossen werden.
Dieser strategische Schritt zielt darauf ab, die proprietäre Perlentechnologie von EMISSION vertikal zu integrieren, um Kernkomponenten für die nächste Generation der Simoa-Plattform von Quanterix zu sichern und OEM-Möglichkeiten mit Drittanbietermodellen zu ermöglichen. Es wird erwartet, dass die Transaktion ab 2026 positiv auf den Umsatz und die Bruttomargen wirkt.
- Strategic vertical integration securing critical technology component
- Potential for new revenue stream through OEM business
- Transaction expected to be accretive to revenue and gross margins by 2026
- Deal structure preserves cash with milestone-based payments
- Initial $10M cash outlay impacts current cash position
- Up to $60M in additional payments may strain future cash flows
- Revenue and margin benefits not expected until 2026
Insights
Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business
“As we expand our technology stack toward higher multi-plex and multi-omic capabilities, it is imperative we control core components,” said Masoud Toloue, Chief Executive Officer of Quanterix. “EMISSION’s proprietary bead technology has already been validated on our upcoming new Simoa platform and will enable us to provide OEM beads to other non-Quanterix platforms. We look forward to welcoming EMISSION’s innovations and colleagues to the Quanterix team.”
EMISSION is based in
Van Chandler, CEO of EMISSION said, “EMISSION was built on our high-quality bead technology and we believe that better beads and ultimately better multi-plex assays should be within everyone’s reach. Having known and worked with the Quanterix team for years, we are excited to join forces, as we support the upcoming Simoa platform and a shared vision for expanding the technology’s reach to all labs.”
Under the terms of the agreement, Quanterix will use cash on hand to acquire EMISSION for
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the transaction, payment of the purchase price and the expected strategic, operational and financial benefits of the acquisition. Forward-looking statements in this press release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release include risks relating to the timing of the closing of the transaction and risks and uncertainties regarding Quanterix’s ability to realize the intended strategic, operational and financial benefits of the transaction, as well as the risk factors and other considerations discussed in Quanterix’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217600200/en/
Media:
Marissa Klaassen
media@quanterix.com
Investor Relations:
Joshua Young
ir@quanterix.com
Source: Quanterix Corporation
FAQ
How much is Quanterix (QTRX) paying for EMISSION acquisition?
When will the QTRX acquisition of EMISSION close?
What are the financial benefits of QTRX's EMISSION acquisition?
How will EMISSION's technology benefit Quanterix (QTRX)?